Forty-two patients were enrolled in a phase I basket trial (NCT02892123) and 71% received an average of five lines of anti-HER2 treatment for metastatic disease and 20 patients had locally advanced or unresectable. Here, ERBB2 is linked to metastatic neoplasm.